STOCK TITAN

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags

Cadrenal Therapeutics (CVKD) announced the exercise of warrants to purchase 285,715 shares of common stock at a reduced price of $16.50 per share, down from the original $26.25. The company will issue new unregistered Series A-1 and A-2 warrants, each for 285,715 shares at $16.50 per share. The gross proceeds are expected to be $4.7 million, which will be used for pivotal Phase 3 trial and partnering activities. The new warrants will have terms of five years and eighteen months respectively, and the company will file a registration statement for the resale of shares.

Cadrenal Therapeutics (CVKD) ha annunciato l’esercizio di warrant per l’acquisto di 285.715 azioni ordinarie a un prezzo ridotto di $16,50 per azione, rispetto al prezzo originale di $26,25. L’azienda emetterà nuovi warrant non registrati di Serie A-1 e A-2, ciascuno per 285.715 azioni a $16,50 per azione. Si prevede che i proventi lordi siano di $4,7 milioni, che saranno utilizzati per una fase cruciale della sperimentazione di Fase 3 e per attività di partnership. I nuovi warrant avranno una durata di cinque anni e diciotto mesi, rispettivamente, e l’azienda presenterà una dichiarazione di registrazione per la rivendita delle azioni.

Cadrenal Therapeutics (CVKD) anunció el ejercicio de warrants para comprar 285,715 acciones ordinarias a un precio reducido de $16.50 por acción, en comparación con el precio original de $26.25. La compañía emitirá nuevos warrants no registrados de las Series A-1 y A-2, cada uno para 285,715 acciones a $16.50 por acción. Se espera que los ingresos brutos sean de $4.7 millones, que se utilizarán para un ensayo clínico pivotal de Fase 3 y actividades de asociación. Los nuevos warrants tendrán plazos de cinco años y dieciocho meses, respectivamente, y la compañía presentará una declaración de registro para la reventa de acciones.

Cadrenal Therapeutics (CVKD)는 $16.50의 할인된 가격으로 285,715주의 보통주를 구매하기 위한 워런트를 행사했다고 발표했습니다. 이는 원래 $26.25에서 하락한 가격입니다. 회사는 각각 $16.50의 가격으로 285,715주를 위한 새로운 비등록 시리즈 A-1 및 A-2 워런트를 발행할 것입니다. 총 수익은 $4.7백만으로 예상되며, 이는 중요한 3상 시험 및 파트너십 활동에 사용될 것입니다. 새로운 워런트의 유효 기간은 각각 5년 및 18개월이며, 회사는 주식 재판매를 위한 등록 신청서를 제출할 것입니다.

Cadrenal Therapeutics (CVKD) a annoncé l'exercice de bons de souscription pour l'achat de 285 715 actions ordinaires à un prix réduit de $16,50 par action, par rapport au prix initial de $26,25. L'entreprise émettra de nouveaux bons de souscription non enregistrés de séries A-1 et A-2, chacun pour 285 715 actions à $16,50 par action. Les produits bruts devraient atteindre $4,7 millions, qui seront utilisés pour un essai clinique pivot de phase 3 et des activités de partenariat. Les nouveaux bons de souscription auront des durées de cinq ans et dix-huit mois respectivement, et l'entreprise déposera une déclaration d'enregistrement pour la revente des actions.

Cadrenal Therapeutics (CVKD) gab die Ausübung von Optionen zum Kauf von 285.715 gewöhnlichen Aktien zu einem reduzierten Preis von $16,50 pro Aktie bekannt, im Vergleich zum ursprünglichen Preis von $26,25. Das Unternehmen wird neue nicht registrierte Serien A-1 und A-2 Optionen ausgeben, jede für 285.715 Aktien zu $16,50 pro Aktie. Die Bruttoerlöse werden voraussichtlich $4,7 Millionen betragen, die für eine entscheidende Phase-3-Studie und Partnerschaftsaktivitäten verwendet werden. Die neuen Optionen haben Laufzeiten von fünf Jahren bzw. achtzehn Monaten, und das Unternehmen wird eine Registrierungserklärung für den Wiederverkauf von Aktien einreichen.

Positive
  • Secured $4.7 million in gross proceeds through warrant exercise
  • Funds allocated for Phase 3 trial advancement
  • Successfully reduced warrant exercise price to increase participation
Negative
  • Warrant exercise price reduced by 37% from $26.25 to $16.50
  • Additional warrant issuance may lead to future dilution
  • New warrants require registration statement filing, adding regulatory complexity

Insights

This warrant exercise represents a significant capital injection for Cadrenal Therapeutics, bringing in $4.7 million in gross proceeds. The transaction involves a complex restructuring of existing warrants at a reduced exercise price of $16.50 from $26.25, indicating a 37% discount to encourage immediate exercise. The company is also issuing new warrants with different terms, effectively creating a longer-term financing structure.

The funding is strategically important for Cadrenal's Phase 3 trial of tecarfarin, their lead anticoagulant candidate. However, the warrant restructuring and issuance of new warrants at a lower price point suggests potential dilution concerns. While the immediate cash infusion strengthens their balance sheet, the additional warrant coverage could create future selling pressure if exercised.

PONTE VEDRA, Fla., Nov. 1, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 285,715 shares of common stock of the originally issued in July 2023, having an exercise price of $26.25 per share, at a reduced exercise price of $16.50 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective post-effective amendment no. 1 to registration statement on Form S-1 on Form S-3 (No. 333-273384). The offering is expected to close on or about November 4, 2024, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series A-1 warrants to purchase up to 285,715 shares of common stock and new unregistered Series A-2 warrants to purchase up to 285,715 shares of common stock. The new warrants will have an exercise price of $16.50 per share and will be immediately exercisable upon issuance. The Series A-1 warrants will have a term of five years from the issuance date and the Series A-2 warrants will have a term of eighteen months from the effective date of the Resale Registration Statement (as defined below).

The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $4.7 million, prior to deducting placement agent fees and estimated offering expenses. The Company intends to use the net proceeds from the offering for its pivotal Phase 3 trial and partnering activities.

The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "1933 Act") and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement (the "Resale Registration Statement") with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, superior chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions. Tecarfarin is anticipated to result in fewer adverse events such as strokes, heart attacks, bleeds and deaths than warfarin, the most commonly used anticoagulant for these patients despite its prevalent side effects, drug-to-drug interactions and frequent dosing changes. Tecarfarin received an orphan drug designation for advanced heart failure patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation. Cadrenal is planning pivotal clinical trials and pursuing clinical and commercial partnerships. The Company's plans also include studying tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties. For more information, please visit: www.cadrenal.com.

Safe Harbor Statement

Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include statements regarding the expected closing of the transaction and the intended use of proceeds. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions and the completion of the offering on the anticipated terms or at all, the Company's anticipated use of proceeds, the Company's ability to complete its planned Phase 3 trial on time and achieve desired results and benefits as expected, and the risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Cadrenal Therapeutics specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-announces-exercise-of-warrants-for-4-7-million-gross-proceeds-302294575.html

SOURCE Cadrenal Therapeutics, Inc.

FAQ

How much did Cadrenal Therapeutics (CVKD) raise through warrant exercise?

Cadrenal Therapeutics raised $4.7 million in gross proceeds through the exercise of warrants at $16.50 per share.

What is the new warrant exercise price for CVKD's recent offering?

The new warrant exercise price is $16.50 per share, reduced from the original price of $26.25 per share.

How will CVKD use the proceeds from the warrant exercise?

CVKD will use the net proceeds for its pivotal Phase 3 trial and partnering activities.

What are the terms of CVKD's new Series A-1 and A-2 warrants?

Series A-1 warrants have a 5-year term, while Series A-2 warrants have an 18-month term from the effective date of the Resale Registration Statement. Both are exercisable at $16.50 per share.

Cadrenal Therapeutics, Inc.

NASDAQ:CVKD

CVKD Rankings

CVKD Latest News

CVKD Stock Data

24.53M
1.09M
34.06%
0.11%
2.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PONTE VEDRA